Analysts think CRVO stock price could increase by 74%
Mar 15, 2025, 11:25 AM
31.32%
What does CRVO do
CervoMed, a Boston-based biotechnology company with 8 employees, focuses on developing neflamapimod for neurodegenerative diseases and is conducting the RewinD-LB Phase 2b trial for dementia with Lewy bodies. The drug aims to modify disease processes and improve synaptic dysfunction.
6 analysts think CRVO stock price will increase by 73.95%. The current median analyst target is $11.22 compared to a current stock price of $6.45. The lowest analysts target is $4.04 and the highest analyst target is $57.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.